These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23945251)

  • 1. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
    Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
    Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
    Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
    Wang X; Cerrone M; Ferretti F; Castrillo N; Maartens G; McClure M; Boffito M
    Int J Antimicrob Agents; 2019 Aug; 54(2):202-206. PubMed ID: 31002950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
    Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
    AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
    Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].
    Wajima T; Koshiba T; Ohno K; Nishimura Y; Kobayashi H; Yoshida N; Nagashima M; Fujiwara T
    Jpn J Antibiot; 2013 Feb; 66(1):1-7. PubMed ID: 23777012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.
    Rungsapphaiboon A; Wacharachaisurapol N; Anugulruengkitt S; Sirikutt P; Phasomsap C; Tawan M; Saisaengjan C; Na Nakorn Y; Paiboon N; Songtaweesin WN; Tawon Y; Cressey TR; Puthanakit T;
    Pediatr Infect Dis J; 2024 Aug; 43(8):789-794. PubMed ID: 39018516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
    McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
    Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
    Freriksen JJM; Schalkwijk S; Colbers AP; Abduljalil K; Russel FGM; Burger DM; Greupink R
    Clin Pharmacol Ther; 2020 Jun; 107(6):1352-1361. PubMed ID: 31868223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
    Imaz A; Martinez-Picado J; Niubó J; Kashuba AD; Ferrer E; Ouchi D; Sykes C; Rozas N; Acerete L; Curto J; Vila A; Podzamczer D
    J Infect Dis; 2016 Nov; 214(10):1512-1519. PubMed ID: 27578849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
    Min S; Song I; Borland J; Chen S; Lou Y; Fujiwara T; Piscitelli SC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):254-8. PubMed ID: 19884365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.